Ascenta Therapeutics Highlights Multiple Data Presentations at Upcoming AACR Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therapeutics, Inc. announced today that its small molecule portfolio of apoptosis-triggering compounds will be featured in three oral presentations and several poster presentations at next week's 2007 Annual Meeting of the American Association for Cancer Research (AACR), to be held in Los Angeles, California April 14-18, 2007.

Ascenta's MDM2 program has been selected for presentation at the "High Impact Late-Breaking Research 1" session on Tuesday, April 17 (Hall A at 3:30pm) and will be presented by Dajun Yang, MD, PhD, Senior Vice President of Research at Ascenta Therapeutics and General Manager of Ascenta's R&D Subsidiary in Shanghai, China. The MDM2 program will also be featured in a talk on Saturday, April 14 (Petree D at 4:15pm) by University of Michigan's Professor Shaomeng Wang, PhD, a co-founder of Ascenta.

Preclinical studies of AT-101, Ascenta's clinical stage, oral pan-Bcl-2 inhibitor, will be featured in an oral presentation by Dr. Yang on Wednesday, April 18 and in several poster presentations authored by Ascenta personnel and collaborating investigators. In a collaboration with scientists at Human Genome Sciences, Inc., studies of HGSI's TRAIL receptor agonist monoclonal antibodies in combination with Ascenta's small molecule XIAP inhibitors, will be presented in a poster session on Tuesday, April 17 (1pm-5pm). The full schedule of presentations featuring Ascenta's technology is as follows: -0-

Date      Time      Title                              Presenter,

                                                        Collaborator

--------- --------- ---------------------------------- --------------

Saturday  4:15pm    Potent, specific, non-peptidic     Shaomeng Wang,

April 14             small molecule inhibitors of the   PhD, U.

                     Human MDM2-p53 interaction as a    Michigan

                     new class of anticancer therapy

--------- --------- ---------------------------------- --------------

Sunday    8am-12pm  Synergistic inhibition of tumor    Xiongwen Zhang

April 15             growth by combined treatment with  MD, PhD

                     the pan Bcl-2 inhibitor AT-101    Ascenta

                     and docetaxel in human cancer      Therapeutics.

                     xenograft models

                    ---------------------------------- --------------

                    A novel small molecular inhibitor  Jason Canner

                     targets the MDM2-p53 interaction   DO, Columbus

                     significantly reducing cell        Children's

                     viability in both embryonal and    Hospital

                     alveolar rhabdomyosarcoma cells

                     with wild-type p53

          --------- ---------------------------------- --------------

          1pm-5pm   AT-101-induced apoptosis in VCaP   Robert Loberg

                     androgen-sensitive cells is        PhD

                     inhibited by the presence of DHT  U. Michigan

                    ---------------------------------- --------------

                    Synergistic effect of AT-101, an   Xiongwen

                     orally active pan-Bcl-2 family     Zhang, MD,

                     protein inhibitor in combination   PhD

                     with dual-Raf/MEK and VEGFR       Ascenta

                     kinase inhibitor sorafenib         Therapeutics

                     (Nexavar(R))

--------- --------- ---------------------------------- --------------

Tuesday   3:30pm    Preclinical characterization of    Dajun Yang,

April 17             MI-219, a novel potent oral small  MD, PhD

                     molecule inhibitor of the MDM2-    Ascenta

                     p53 interaction                    Therapeutics

          --------- ---------------------------------- --------------

          1pm-5pm   Synergistic anti-tumor effect with Nathalie

                     combination of a novel small       Bruey-Sedano,

                     molecule Smac mimetic compound     PhD,

                     (SM-164) and agonist TRAIL-R      Ascenta

                     monoclonal Abs (mapatumumab &      Therapeutics

                     lexatumumab).                     Human Genome

                                                        Sciences

--------- --------- ---------------------------------- --------------

Wednesday 8:30am-   In vivo efficacy of AT-101, an     Dajun Yang,

April 18   12pm      orally active pan-Bcl-2 family     MD, PhD,

                     protein inhibitor in combination   Ascenta

                     with the ErbB1 tyrosine kinase     Therapeutics

                     inhibitor erlotinib (Tarceva(R))

                    ---------------------------------- --------------

                    A novel pan inhibitor of Bcl-2 and Xiongwen

                     Mcl-1, apogossypolone (ApoG2),     Zhang, MD,

                     with superior stability and        PhD

                     improved activity against human   Ascenta

                     leukemia and lymphoma cells.       Therapeutics

--------- --------- ---------------------------------- --------------


Date       Time      Session                             Type/Location

                                                         Abstract #

---------- --------- ----------------------------------- -------------

Saturday   4:15pm    Alternative approaches to small     Oral

April 14              molecule drug discovery protein-    Presentation

                      protein interaction                 in Petree D

---------- --------- ----------------------------------- -------------

Sunday     8am-12pm  Experimental and Molecular          Poster in

April 15              Therapeutics 4                      Exhibit

                                                          Hall. Poster

                                                          section 29.


                                                         Abstract #

                                                          725

                     ----------------------------------- -------------

                     Experimental and Molecular          Poster in

                      Therapeutics 4                      Exhibit Hall

                                                         Board 4-

                                                          Poster

                                                          Section 21.


                                                         Abstract #

                                                          509

           --------- ----------------------------------- -------------

           1pm-5pm   Experimental and Molecular          Poster in

                      Therapeutics                        Exhibit Hall

                                                         Poster

                                                          Section 9


                                                         Abstract #

                                                          983

                     ----------------------------------- -------------

                     Experimental and Molecular          Poster in

                      Therapeutics 9                      Exhibit Hall

                                                         Poster

                                                          Section 28


                                                         Abstract #

                                                          1452

---------- --------- ----------------------------------- -------------

Tuesday    3:30pm    High Impact Late-Breaking Research  Oral

April 17              1                                   Presentation

                                                          in Hall A


                                                         Abstract #

                                                          LB-365

           --------- ----------------------------------- -------------

           1pm-5pm   Experimental and Molecular          Poster in

                      Therapeutics 42                     Exhibit Hall

                                                         Poster

                                                          Section 31


                                                         Abstract #

                                                          4871

---------- --------- ----------------------------------- -------------

Wednesday  8:30am-   Experimental and Molecular          Oral

April 18    12pm      Therapeutics 51                     Presentation

                     Minisymposium Session

                                                         Abstract #

                                                          5737

                     ----------------------------------- -------------

                     Cellular and Molecular Biology 64   Poster in

                                                          Exhibit Hall

                                                          -Poster

                                                          Section 11


                                                         Abstract #

                                                          5182

---------- --------- ----------------------------------- -------------

Founded in 2003, Ascenta is a privately-held biopharmaceutical company that discovers and develops targeted new medicines for the treatment of cancer. The company has offices in San Diego, California and Malvern, Pennsylvania, and has a preclinical research facility in Shanghai, China. Its technology, licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan, is focused on discovering molecules that hit vulnerable targets in endogenous apoptosis pathways to shut down cell growth and proliferation in cancer cells.

For additional information on Ascenta Therapeutics, please visit the company's website at www.ascenta.com.

Contact

Ascenta Therapeutics, Inc.
Mark Benedyk PhD
Vice President, Business Development
858-436-1200
mbenedyk@ascenta.com

Posted: April 2007

View comments

Hide
(web4)